NCT04171739View on ClinicalTrials.gov

Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

February 11, 2020

Study Completion Date

February 11, 2020

Conditions

Healthy

Interventions

DRUG

Itraconazole oral solution

200 mg once daily on Days 6 to 15

DRUG

Rifampicin Oral Capsule

600 mg once daily on Days 6 to 15

DRUG

Olorofim

Single oral dose on Days 1 and 11

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research, London

Sponsors

Lead Sponsor

F2G Biotech GmbH

All Listed Sponsors

collaborator

Hammersmith Medicines Research

OTHER

lead

F2G Biotech GmbH

INDUSTRY